Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013;45:180–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chmielecki J, Crago AM, Rosenberg M, et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013;45:131–2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohajeri A, Tayebwa J, Collin A, et al. Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes Cancer. 2013;52:873–86.

Article  CAS  PubMed  Google Scholar 

Gengler C, Guillou L. Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. Histopathology. 2006;48:63–74.

Article  CAS  PubMed  Google Scholar 

Park MS, Araujo DM. New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Curr Opin Oncol. 2009;21:327–31.

Article  PubMed  Google Scholar 

Salas S, Resseguier N, Blay JY, et al. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. Ann Oncol. 2017;28:1979–87.

Article  CAS  PubMed  Google Scholar 

van Houdt WJ, Westerveld CM, Vrijenhoek JE, et al. Prognosis of solitary fibrous tumors: a multicenter study. Ann Surg Oncol. 2013;20:4090–5.

Article  PubMed  Google Scholar 

de Bernardi A, Dufresne A, Mishellany F, Blay JY, Ray-Coquard I, Brahmi M. Novel therapeutic options for solitary fibrous tumor: antiangiogenic therapy and beyond. Cancers. 2022;14:1064.

Article  PubMed  PubMed Central  Google Scholar 

Ben-David U, Beroukhim R, Golub TR. Genomic evolution of cancer models: perils and opportunities. Nat Rev Cancer. 2019;19:97–109.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saito S, Morita K, Kohara A, et al. Use of BAC array CGH for evaluation of chromosomal stability of clinically used human mesenchymal stem cells and of cancer cell lines. Hum Cell. 2011;24:2–8.

Article  PubMed  Google Scholar 

Ben-David U, Siranosian B, Ha G, et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018;560:325–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang W, Soares J, Greninger P, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955–61.

Article  CAS  PubMed  Google Scholar 

Barretina J, Caponigro G, Stransky N, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Mol Cancer Res. 2016;14:3–13.

Article  CAS  PubMed  Google Scholar 

Hattori E, Oyama R, Kondo T. Systematic review of the current status of human sarcoma cell lines. Cells. 2019;8:157.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee JY, Guan P, Lim AH, et al. Establishment and characterization of a patient-derived solitary fibrous tumor/hemangiopericytoma cell line model. Hum Cell. 2024;37:310–22.

Article  CAS  PubMed  Google Scholar 

Ghanim B, Baier D, Pirker C, et al. Trabectedin is active against two novel, patient-derived solitary fibrous pleural tumor cell lines and synergizes with ponatinib. Cancers. 2022;14:5602.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshimatsu Y, Noguchi R, Tsuchiya R, et al. Establishment and characterization of NCC-ASPS1-C1: a novel patient-derived cell line of alveolar soft-part sarcoma. Hum Cell. 2020;33:1302.

Article  CAS  PubMed  Google Scholar 

Bairoch A. The cellosaurus, a cell-Line knowledge resource. J Biomol Tech. 2018;29:25–38.

Article  PubMed  PubMed Central  Google Scholar 

Klemperer P, Rabin CB. Primary neoplasms of the pleura. A report of five cases. Arch Pathol. 1931;11:385–412.

Google Scholar 

Barthelmeß S, Geddert H, Boltze C, et al. Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features. Am J Pathol. 2014;184:1209–18.

Article  PubMed  Google Scholar 

Bieg M, Moskalev EA, Will R, et al. Gene expression in solitary fibrous tumors (SFTs) correlates with anatomic localization and NAB2-STAT6 gene fusion variants. Am J Pathol. 2021;191:602–17.

Article  CAS  PubMed  Google Scholar 

Ishihara S, Ogura K, Maejima A, et al. Predictive value of peripheral blood markers in soft tissue sarcoma patients treated with eribulin. Jpn J Clin Oncol. 2023;53:494–500.

Article  PubMed  Google Scholar 

Kawai A, Narahara H, Takahashi S, et al. Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study. BMC Cancer. 2022;22:528.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawai A, Yonemori K, Takahashi S, Araki N, Ueda T. Systemic therapy for soft tissue sarcoma: proposals for the optimal use of pazopanib, trabectedin, and eribulin. Adv Ther. 2017;34:1556–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawai A, Araki N, Naito Y, et al. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol. 2017;47:137–44.

Article  PubMed  Google Scholar 

Logan TF. Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer. Curr Oncol Rep. 2013;15:83–90.

Article  CAS  PubMed  Google Scholar 

Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31:181–6.

Article  CAS  PubMed  Google Scholar 

Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS ONE. 2013;8: e54014.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Knubel KH, Pernu BM, Sufit A, Nelson S, Pierce AM, Keating AK. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme. Oncotarget. 2014;5:1338–51.

Article  PubMed  PubMed Central  Google Scholar 

Goździk-Spychalska J, Szyszka-Barth K, Spychalski L, et al. C-MET inhibitors in the treatment of lung cancer. Curr Treat Options Oncol. 2014;15:670–82.

Article  PubMed  Google Scholar 

Rayson D, Lupichuk S, Potvin K, et al. Canadian cancer trials group IND197: a phase II study of foretinib in patients with estrogen receptor, progest